ROC down 22% since the July offer, you're right. Interestingly Roches's current 56% portion of DNA is worth about 48bn and only represents 43% of Roche's total mkt cap of $113bn. Of course their rights to DNA drugs in ROW are a big part of the rest of Roche's value - their own product portfolio can't be worth a whole lot - but maybe their diagnostics biz is worth quite a bit? Anyway, imo it is not in their interest to screw up Genentech, but they will be unable to help themselves if the merger deal is struck.
Market Data 
Markets 
AI
